These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 17869513)

  • 21. Synthesis and dipeptidyl peptidase inhibition of N-(4-substituted-2,4-diaminobutanoyl)piperidines.
    Soroka A; Van der Veken P; De Meester I; Lambeir AM; Maes MB; Scharpé S; Haemers A; Augustyns K
    Bioorg Med Chem Lett; 2006 Sep; 16(18):4777-9. PubMed ID: 16844373
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A triumph for physiology driving drug discovery: the potential impact of dipeptidyl peptidase-IV inhibitors in type 2 diabetes.
    Donnelly R
    Diabetes Obes Metab; 2007 Mar; 9(2):151-2. PubMed ID: 17300590
    [No Abstract]   [Full Text] [Related]  

  • 23. Inhibition of dipeptidyl peptidase IV (DPP IV) is one of the mechanisms explaining the hypoglycemic effect of berberine.
    Al-masri IM; Mohammad MK; Tahaa MO
    J Enzyme Inhib Med Chem; 2009 Oct; 24(5):1061-6. PubMed ID: 19640223
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of potent, selective, and orally bioavailable oxadiazole-based dipeptidyl peptidase IV inhibitors.
    Xu J; Wei L; Mathvink RJ; Edmondson SD; Eiermann GJ; He H; Leone JF; Leiting B; Lyons KA; Marsilio F; Patel RA; Patel SB; Petrov A; Scapin G; Wu JK; Thornberry NA; Weber AE
    Bioorg Med Chem Lett; 2006 Oct; 16(20):5373-7. PubMed ID: 16919457
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
    Augeri DJ; Robl JA; Betebenner DA; Magnin DR; Khanna A; Robertson JG; Wang A; Simpkins LM; Taunk P; Huang Q; Han SP; Abboa-Offei B; Cap M; Xin L; Tao L; Tozzo E; Welzel GE; Egan DM; Marcinkeviciene J; Chang SY; Biller SA; Kirby MS; Parker RA; Hamann LG
    J Med Chem; 2005 Jul; 48(15):5025-37. PubMed ID: 16033281
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fluoro-olefins as peptidomimetic inhibitors of dipeptidyl peptidases.
    Van der Veken P; Senten K; Kertèsz I; De Meester I; Lambeir AM; Maes MB; Scharpé S; Haemers A; Augustyns K
    J Med Chem; 2005 Mar; 48(6):1768-80. PubMed ID: 15771423
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of potent dipeptidyl peptidase IV inhibitors derived from β-aminoamides bearing substituted [1,2,3]-triazolopiperidines for the treatment of type 2 diabetes.
    Shan Z; Peng M; Fan H; Lu Q; Lu P; Zhao C; Chen Y
    Bioorg Med Chem Lett; 2011 Mar; 21(6):1731-5. PubMed ID: 21334204
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gamma-amino-substituted analogues of 1-[(S)-2,4-diaminobutanoyl]piperidine as highly potent and selective dipeptidyl peptidase II inhibitors.
    Senten K; Van Der Veken P; De Meester I; Lambeir AM; Scharpé S; Haemers A; Augustyns K
    J Med Chem; 2004 May; 47(11):2906-16. PubMed ID: 15139769
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and structure-activity relationships of potent 4-fluoro-2-cyanopyrrolidine dipeptidyl peptidase IV inhibitors.
    Fukushima H; Hiratate A; Takahashi M; Mikami A; Saito-Hori M; Munetomo E; Kitano K; Chonan S; Saito H; Suzuki A; Takaoka Y; Yamamoto K
    Bioorg Med Chem; 2008 Apr; 16(7):4093-106. PubMed ID: 18243000
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications.
    Ahrén B
    Diabetes Care; 2007 Jun; 30(6):1344-50. PubMed ID: 17337494
    [No Abstract]   [Full Text] [Related]  

  • 31. DPP-4 inhibitors. A new class of drugs for type 2 diabetes.
    Marino MT
    Diabetes Self Manag; 2008; 25(4):60, 62-4. PubMed ID: 18717028
    [No Abstract]   [Full Text] [Related]  

  • 32. Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice.
    Kim SJ; Nian C; Doudet DJ; McIntosh CH
    Diabetes; 2008 May; 57(5):1331-9. PubMed ID: 18299314
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of potent, selective, and orally bioavailable pyridone-based dipeptidyl peptidase-4 inhibitors.
    Xu J; Wei L; Mathvink R; Edmondson SD; Mastracchio A; Eiermann GJ; He H; Leone JF; Leiting B; Lyons KA; Marsilio F; Patel RA; Petrov A; Wu JK; Thornberry NA; Weber AE
    Bioorg Med Chem Lett; 2006 Mar; 16(5):1346-9. PubMed ID: 16332437
    [TBL] [Abstract][Full Text] [Related]  

  • 34. From lead to preclinical candidate: optimization of beta-homophenylalanine based inhibitors of dipeptidyl peptidase IV.
    Nordhoff S; López-Canet M; Hoffmann-Enger B; Bulat S; Cerezo-Gálvez S; Hill O; Rosenbaum C; Rummey C; Thiemann M; Matassa VG; Edwards PJ; Feurer A
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4818-23. PubMed ID: 19576767
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of non-covalent dipeptidyl peptidase IV inhibitors which induce a conformational change in the active site.
    Sheehan SM; Mest HJ; Watson BM; Klimkowski VJ; Timm DE; Cauvin A; Parsons SH; Shi Q; Canada EJ; Wiley MR; Ruehter G; Evers B; Petersen S; Blaszczak LC; Pulley SR; Margolis BJ; Wishart GN; Renson B; Hankotius D; Mohr M; Zechel JC; Michael Kalbfleisch J; Dingess-Hammond EA; Boelke A; Weichert AG
    Bioorg Med Chem Lett; 2007 Mar; 17(6):1765-8. PubMed ID: 17239592
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond.
    Inzucchi SE; McGuire DK
    Circulation; 2008 Jan; 117(4):574-84. PubMed ID: 18227398
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 3-[2-((2S)-2-cyano-pyrrolidin-1-yl)-2-oxo-ethylamino]-3-methyl-butyramide analogues as selective DPP-IV inhibitors for the treatment of type-II diabetes.
    Coumar MS; Chang CN; Chen CT; Chen X; Chien CH; Tsai TY; Cheng JH; Wu HY; Han CH; Wu SH; Huang YW; Hsu T; Hsu LJ; Chao YS; Hsieh HP; Jiaang WT
    Bioorg Med Chem Lett; 2007 Mar; 17(5):1274-9. PubMed ID: 17194587
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dipeptidyl peptidase IV inhibitors for the treatment of diabetes.
    Weber AE
    J Med Chem; 2004 Aug; 47(17):4135-41. PubMed ID: 15293982
    [No Abstract]   [Full Text] [Related]  

  • 39. (3R,4S)-4-(2,4,5-Trifluorophenyl)-pyrrolidin-3-ylamine inhibitors of dipeptidyl peptidase IV: synthesis, in vitro, in vivo, and X-ray crystallographic characterization.
    Wright SW; Ammirati MJ; Andrews KM; Brodeur AM; Danley DE; Doran SD; Lillquist JS; Liu S; McClure LD; McPherson RK; Olson TV; Orena SJ; Parker JC; Rocke BN; Soeller WC; Soglia CB; Treadway JL; Vanvolkenburg MA; Zhao Z; Cox ED
    Bioorg Med Chem Lett; 2007 Oct; 17(20):5638-42. PubMed ID: 17822893
    [TBL] [Abstract][Full Text] [Related]  

  • 40. (2S,3S)-3-Amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-[1,2,4]triazolo[1,5-a]-pyridin-6-ylphenyl)butanamide: a selective alpha-amino amide dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
    Edmondson SD; Mastracchio A; Mathvink RJ; He J; Harper B; Park YJ; Beconi M; Di Salvo J; Eiermann GJ; He H; Leiting B; Leone JF; Levorse DA; Lyons K; Patel RA; Patel SB; Petrov A; Scapin G; Shang J; Roy RS; Smith A; Wu JK; Xu S; Zhu B; Thornberry NA; Weber AE
    J Med Chem; 2006 Jun; 49(12):3614-27. PubMed ID: 16759103
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.